Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISM Extension Study of Cobomarsen After Vorinostat in Mycosis Fungoides
2018-003748-22Phase 2Terminated
- Sponsor
- Viridian Therapeutics
- Start
- Feb 2019
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cobomarsen in mycosis fungoides (MF), sponsored by Viridian Therapeutics. Started Feb 2019; status: terminated.
02
Drugs
cobomarsen
03
Conditions
mycosis fungoides (MF)
Beyond the preview
Go deeper on 2018-003748-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003748-22.